Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance

• Egile Nagusiak: Joseph Fiore (Egilea), Maribel Miranda Co-van der Mee (Egilea), Andrés Maldonado (Egilea), Lisa Glasser (Egilea), Phil Watson (Egilea)
• Formatua: Liburua
• Argitaratua: SAGE Publishing, 2021-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

An adjuvanted recombinant zoster vaccine (RZV) is licensed for the prevention of herpes zoster. This paper reviews its safety and reactogenicity. A pooled analysis of two pivotal randomized Phase-3 trials (NCT01165177, NCT01165229) in adults ⩾50 years found that more solicited adverse events (AEs) w...